Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.51 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.51 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | OTC | P00480 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | TGM2 | P21980 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817462 | 1.00 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL10507212 | 1.00 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL20446016 | 1.00 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL20446014 | 0.98 | DDAH1 (0.50) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463086 | 0.95 | DDAH1 (0.56) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463087 | 0.95 | DDAH1 (0.56) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463174 | 0.87 | ALDH1A1 (0.45) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463173 | 0.87 | ALDH1A1 (0.45) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL20446015 | 0.85 | TGM2 (0.50) | ZDHHC20ZDHHC2DDAH1GSRTGM2 | |
| SCHEMBL20704725 | 0.84 | GSR (0.50) | DDAH1GSROTCARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230016396-A1 | METHODS OF POLYPEPTIDE SEQUENCING | Encodia, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220409737-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS BIOPHARMA AG (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-4051320-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS Pharma AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114641316-A | Biocompatible polymeric drug carriers for delivery of active agents | CIS制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20210174903-A1 | ENHANCED PROTEIN STRUCTURE PREDICTION USING PROTEIN HOMOLOG DISCOVERY AND CONSTRAINED DISTOGRAMS | Protein Evolution Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210174893-A1 | PROTEIN STRUCTURE PREDICTION | Homodeus, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| US-11008414-B2 | Polymer materials for contact lens applications | CIS PHARMA AG (CH) | 2021-05-18 | — | — | US | disclosed |
| US-20210128735-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | CIS BIOPHARMA AG (CH) | 2021-05-06 | — | — | US | disclosed |
| WO-2021084087-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS PHARMA AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| US-20210130395-A1 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3790590-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | CIS Pharma AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| US-20200283560-A1 | New polymer materials for contact lens applications | CIS PHARMA AG (CH) | 2020-09-10 | — | — | US | disclosed |
| WO-2019215207-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | CIS PHARMA AG (CH) | 2019-11-14 | — | — | WO | disclosed |
| EP-3356433-B1 | NEW POLYMER MATERIALS FOR CONTACT LENS APPLICATIONS | CIS PHARMA AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3356433-A1 | NEW POLYMER MATERIALS FOR CONTACT LENS APPLICATIONS | CIS Pharma AG (CH) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | ZDHHC20 3427/4885ZDHHC2 1141/4885DDAH1 82/4885 |
| US-20220409737-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CD47, DNPEP, MSR1 | ZDHHC20 4575/4885ZDHHC2 4314/4885DDAH1 473/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | ZDHHC20 727/4885ZDHHC2 683/4885DDAH1 1340/4885 |
| US-20210128735-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | LNPEP, PAICS, CD47 | ZDHHC20 4687/4885ZDHHC2 4469/4885DDAH1 870/4885 |
| US-20200283560-A1 | New polymer materials for contact lens applications | CRYAA, CRYAB, BCAT1 | ZDHHC20 3848/4885ZDHHC2 4034/4885DDAH1 99/4885 |
| US-20210130395-A1 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | CD2BP2, FCGR2A, FCGR3B | ZDHHC20 323/4885ZDHHC2 177/4885DDAH1 2231/4885 |
| US-11008414-B2 | Polymer materials for contact lens applications | CRYAA, BCAT1, CRYAB | ZDHHC20 3984/4885ZDHHC2 4069/4885DDAH1 168/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | ZDHHC20 1159/4885ZDHHC2 954/4885DDAH1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.